Nalani Hunsaker, PA
Medical · Escondido, CANPI 1144769886
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,579 of the $38,808 with a category attached, or 63.3%. Medtronic accounts for 98.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $23,557 and has fallen 99.9% since, to $14 in 2025. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $241.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$38K
- Xeris Pharmaceuticals, Inc.$120
- Insulet Corporation$106
- Tandem Diabetes Care, Inc.$103
- Lilly USA, LLC$103
- AstraZeneca$91
- plus $247 from 9 others
What the payments were for
- Consulting fees$1,3604%
- Speaking & faculty fees$24,57963%
- Travel & lodging$10,35627%
- Food & beverage$2,5126%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 119 | $38,038 |
| Xeris Pharmaceuticals, Inc. | 6 | $120 |
| Insulet Corporation | 5 | $106 |
| Tandem Diabetes Care, Inc. | 4 | $103 |
| Lilly USA, LLC | 5 | $103 |
| AstraZeneca | 5 | $91 |
| Abbott | 8 | $62 |
| Nevro Corp. | 1 | $32 |
| AbbVie | 2 | $29 |
| Vifor Pharma, Inc. | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Dexcom, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $21 |
| Amgen | 1 | $18 |
| Verity Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$22,841
- MINIMED 780G$5,254
- Minimed 770G System$2,550
- InPen$1,105
- INPEN SMART INSULIN DELIVERY SYSTEM$850
How this compares
$38,808 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $128,203 |
| MounjaroTirzepatide | 42 | $56,292 |
| RybelsusSemaglutide | 40 | $50,601 |
| FarxigaDapagliflozin Propanediol | 29 | $22,826 |
| TrulicityDulaglutide | 22 | $22,778 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $19,783 |
| JardianceEmpagliflozin | 22 | $19,652 |
| Gvoke Hypopen 2-PackGlucagon | 19 | $12,070 |
| Novolog FlexpenInsulin Aspart | 15 | $3,684 |
| HumalogInsulin Lispro | 11 | $2,657 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $1,493 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 13 | $1,384 |
| Insulin Lispro | 14 | $856 |
| Atorvastatin Calcium | 16 | $812 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $103 | $82,58489 claims |
| AstraZenecaFarxiga | $91 | $22,82629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Escondido
- Jessica MattsonEscondido$23K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- David DoriguzziLancaster$166K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.